Utilization of Boron Compounds for the Modification of Suberoyl Anilide Hydroxamic Acid as Inhibitor of Histone Deacetylase Class II Homo sapiens.

Histone deacetylase (HDAC) has a critical function in regulating gene expression. The inhibition of HDAC has developed as an interesting anticancer research area that targets biological processes such as cell cycle, apoptosis, and cell differentiation. In this study, an HDAC inhibitor that is available commercially, suberoyl anilide hydroxamic acid (SAHA), has been modified to improve its efficacy and reduce the side effects of the compound.

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer.

Cervical cancer is second most common cancer in woman worldwide. Cervical cancer caused by human papillomavirus (HPV) oncogene. Inhibition of histone deacetylase (HDAC) activity has been known as a potential strategy for cancer therapy.

Rational addition of capping groups to the phosphomolybdate Keggin anion [PMo12O40](3-) by mild, non-aqueous reductive aggregation.

Controlled reductive assembly of capped Keggin anions [PMo(12)O(40)(ML(m))(n)](3-) has been achieved by reduction of [PMo(12)O(40)](3-) with sodium-mercury amalgam in the presence of metal halides, as exemplified by the rational syntheses of mono-capped [PMo(12)O(40){Co(MeCN)(2)}](3-) and bi-capped [PMo(12)O(40)(VO)(2)](3-) and [PMo(12)O(40)Sb(2)](3-).